Melanoma Clinical Trials in Baltimore

Showing 241-260 of 320 trials

Trial of Vemurafenib and Cobimetinib in Patients With Advanced BRAFV600 Mutant Melanoma

NCT02427893

This trial explores the immunologic effects of vemurafenib (BRAF inhibitor) and cobimetinib (MEK inhibitor), administered alone and in combination, to patients with advanced BRAF V600E/K mutant melanoma.

Melanoma

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsStarted Aug 2015

Baltimore, Maryland, United States

TERMINATEDPhase 2< 1 mile

Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Stage IV Melanoma

NCT01120275

This phase II trial is studying how well gamma-secretase/Notch signalling pathway inhibitor RO4929097 works in treating patients with stage IV melanoma. Gamma-secretase/Notch signalling pathway inhibitor RO4929097 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Acral Lentiginous Malignant MelanomaLentigo Maligna Malignant MelanomaNodular Malignant Melanoma+4 more

National Cancer Institute (NCI)36 participantsStarted Oct 2010

Mobile, Alabama, United States • Fairbanks, Alaska, United States • Tucson, Arizona, United States +175 more locations

Trial of Vemurafenib and Cobimetinib in Patients With Advanced BRAFV600 Mutant Melanoma

Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Stage IV Melanoma

Melanoma Trials in Other Cities

Safety Study of a Melanoma Vaccine (GVAX) With or Without Cyclophosphamide in Patients With Surgically Resected Melanoma

Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

Phase II, 2nd Line Melanoma - RAND Monotherapy

Cell Therapy for Metastatic Melanoma Using CD8 Enriched Tumor Infiltrating Lymphocytes

Phase II Study of Aldesleukin (IL-2) Following the Administration of Zanolimumab (Anti-CD4mAb) in Metastatic Melanoma and Metastatic Renal Cancer

Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Recurrent Metastatic Melanoma

Inhaled Sargramostim in Treating Patients With Melanoma Metastatic to the Lung

In Vivo Confocal Microscopy Study of Pigmented Conjunctival Lesions

Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma

Safety, Tolerability and Efficacy Study of the Monoclonal Antibody, CT-011, in Patients With Metastatic Melanoma

Vaccine Therapy Compared With Interferon Alfa in Treating Patients With Stage III Melanoma

CCI-779 in Treating Patients With Metastatic Melanoma

Study to Compare the Effect of Ipilimumab Retreatment With That of Chemotherapy in Advanced Melanoma

Safety Study of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma

Expanded Access Protocol of Talimogene Laherparepvec for Subjects With Unresected, Stage lllB to IVM1c Melanoma

Treatment for Subjects With Unresectable Stage III or Stage IV Melanoma

Phase II Study to Determine Predictive Markers of Response to BMS-734016 (MDX-010)

Comparison of AZD6244 in Combination With Dacarbazine Versus (vs) Dacarbazine Alone in BRAF Mutation Positive Melanoma Patients

Other Conditions in Baltimore